Landscape of germline
BRCA1
BRCA2
breast cancer
germline mutation
ovarian cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
23
05
2023
accepted:
27
07
2023
medline:
4
9
2023
pubmed:
4
9
2023
entrez:
4
9
2023
Statut:
epublish
Résumé
There is an increasing amount of data from Latin America on the characterization of BRCA variants; however, there is limited information from Peru. We conducted a retrospective study to describe germline pathogenic/likely pathogenic(P/LP) variants and variants of uncertain/unknown significance (VUS) in the BRCA1 and BRCA2 genes in Peru, in patients with breast and ovarian cancer, candidates for treatment with poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors. The patients were evaluated during the period 2019-2021. Genomic DNA was isolated from peripheral blood samples and targeted sequencing was performed using the Ampliseq BRCA panel. Genetic variant interpretation was carried out in accordance with the recommendations of the American College of Medical Genetics and ClinVar. During this period, 525 patients (143 with breast cancer and 382 with ovarian cancer) were studied. We found that 14.7% (21/143) of breast cancer patients and 20.7% (79/382) of ovarian cancer patients were carriers of P/LP variants in BRCA1/2. The most frequent pathogenic variants detected in BRCA1 were c.2105dupT (BIC: 2224insT, n=12, 18.75%), c.68_69delAG (BIC: 185delAG, n=6, 9.38%), c.140G>T and c.815_824dupAGCCATGTGG (n=5, 7.81%), while in BRCA2 were c.8023A>G (n=6, 16.67%), c.6024dupG (BIC: 6252insG, n=4, 11.11%), and c.9235delG (BIC: 9463delG, n=3, 8.33%). Regarding VUS, we found that 6.99% (10/143) of breast cancer patients and 7.33% (28/382) of ovarian cancer patients were carriers of a VUS in BRCA1/2. For BRCA1, the most frequent VUS was c.93C>G (n=2), and for BRCA2, c.5465A>T (n=4), c.3101T>C (n=3), c.205C>A and c.437T>C (n=2). We found a frequency of 14.7% germline mutations in breast cancer patients and 20.7% in ovarian cancer patients. The most recurrent mutations were BRCA1 c.2105dupT and BRCA2 c.8023A>G. We found that BRCA2 c.8023A>G, c.6024dupG, and c.9235delG were not previously reported in Peruvian patients. BRCA1 c.2344dupA is a novel mutation that has not been previously reported in any database. The frequency of VUS in our cohort was 7.2%.
Sections du résumé
Background
UNASSIGNED
There is an increasing amount of data from Latin America on the characterization of BRCA variants; however, there is limited information from Peru. We conducted a retrospective study to describe germline pathogenic/likely pathogenic(P/LP) variants and variants of uncertain/unknown significance (VUS) in the BRCA1 and BRCA2 genes in Peru, in patients with breast and ovarian cancer, candidates for treatment with poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitors.
Methods
UNASSIGNED
The patients were evaluated during the period 2019-2021. Genomic DNA was isolated from peripheral blood samples and targeted sequencing was performed using the Ampliseq BRCA panel. Genetic variant interpretation was carried out in accordance with the recommendations of the American College of Medical Genetics and ClinVar. During this period, 525 patients (143 with breast cancer and 382 with ovarian cancer) were studied.
Results
UNASSIGNED
We found that 14.7% (21/143) of breast cancer patients and 20.7% (79/382) of ovarian cancer patients were carriers of P/LP variants in BRCA1/2. The most frequent pathogenic variants detected in BRCA1 were c.2105dupT (BIC: 2224insT, n=12, 18.75%), c.68_69delAG (BIC: 185delAG, n=6, 9.38%), c.140G>T and c.815_824dupAGCCATGTGG (n=5, 7.81%), while in BRCA2 were c.8023A>G (n=6, 16.67%), c.6024dupG (BIC: 6252insG, n=4, 11.11%), and c.9235delG (BIC: 9463delG, n=3, 8.33%). Regarding VUS, we found that 6.99% (10/143) of breast cancer patients and 7.33% (28/382) of ovarian cancer patients were carriers of a VUS in BRCA1/2. For BRCA1, the most frequent VUS was c.93C>G (n=2), and for BRCA2, c.5465A>T (n=4), c.3101T>C (n=3), c.205C>A and c.437T>C (n=2).
Conclusion
UNASSIGNED
We found a frequency of 14.7% germline mutations in breast cancer patients and 20.7% in ovarian cancer patients. The most recurrent mutations were BRCA1 c.2105dupT and BRCA2 c.8023A>G. We found that BRCA2 c.8023A>G, c.6024dupG, and c.9235delG were not previously reported in Peruvian patients. BRCA1 c.2344dupA is a novel mutation that has not been previously reported in any database. The frequency of VUS in our cohort was 7.2%.
Identifiants
pubmed: 37664050
doi: 10.3389/fonc.2023.1227864
pmc: PMC10470619
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1227864Informations de copyright
Copyright © 2023 Ferreyra, Rosas, Cock-Rada, Araujo, Bravo, Doimi, Casas, Clavo, Pinto and Belmar-López.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Fam Cancer. 2017 Oct;16(4):477-489
pubmed: 28477318
Hum Mol Genet. 2014 Sep 1;23(17):4703-9
pubmed: 24728189
NPJ Genom Med. 2020 Jan 31;5:8
pubmed: 32025337
Eur J Hum Genet. 2013 Feb;21(2):212-6
pubmed: 22763381
Clin Genet. 2015 Oct;88(4):371-5
pubmed: 25256238
Mol Genet Genomic Med. 2015 Mar;3(2):121-9
pubmed: 25802882
Hum Mutat. 2003 Oct;22(4):301-12
pubmed: 12955716
Genes (Basel). 2019 Feb 18;10(2):
pubmed: 30781715
Hered Cancer Clin Pract. 2018 Feb 27;16:6
pubmed: 29492181
Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):498-505
pubmed: 25371446
Ecancermedicalscience. 2019 Jan 22;13:897
pubmed: 30792814
Sci Rep. 2021 Apr 19;11(1):8485
pubmed: 33875706
Adv Exp Med Biol. 2020;1292:1-12
pubmed: 29687286
Hered Cancer Clin Pract. 2018 Jan 10;16:3
pubmed: 29339979
Fam Cancer. 2017 Jan;16(1):1-16
pubmed: 27495310
J Med Genet. 2021 Nov;58(11):752-759
pubmed: 32963034
Fam Cancer. 2018 Jan;17(1):23-30
pubmed: 28528518
Cancer. 2015 Feb 1;121(3):372-8
pubmed: 25236687
Breast Cancer Res Treat. 2014 Apr;144(3):635-42
pubmed: 24578176
Nature. 2005 Apr 14;434(7035):917-21
pubmed: 15829967
Front Genet. 2022 Jun 06;13:863956
pubmed: 35734436
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Oncotarget. 2016 Dec 6;7(49):80465-80481
pubmed: 27741520
Genet Med. 2010 Nov;12(11):726-35
pubmed: 20921897
Cancer Lett. 2010 Dec 8;298(2):258-63
pubmed: 20727672
Contemp Oncol (Pozn). 2013;17(1):34-7
pubmed: 23788959
Aging (Albany NY). 2021 Mar 11;13(6):8975-8988
pubmed: 33705352
Cancers (Basel). 2021 May 31;13(11):
pubmed: 34072659
J Natl Compr Canc Netw. 2022 Jun;20(6):691-722
pubmed: 35714673
Genet Res (Camb). 2020 Aug 10;102:e6
pubmed: 32772980
Breast Cancer Res Treat. 2023 Jan;197(2):387-395
pubmed: 36367610
Cancer. 2015 Dec 1;121(23):4173-80
pubmed: 26287763
Mol Genet Genomic Med. 2017 Jun 28;5(5):481-494
pubmed: 28944232
Clin Genet. 2015 Mar;87(3):288-92
pubmed: 24528374
Cancers (Basel). 2020 Aug 17;12(8):
pubmed: 32824581
N Engl J Med. 2019 Dec 19;381(25):2416-2428
pubmed: 31851799
Hum Mutat. 2018 May;39(5):593-620
pubmed: 29446198
Biol Res. 2017 Oct 6;50(1):35
pubmed: 28985766
Genet Mol Biol. 2012 Jul;35(3):599-602
pubmed: 23055798
BMC Cancer. 2013 May 17;13:243
pubmed: 23683081
Oncologist. 2019 Jul;24(7):e475-e479
pubmed: 30541753
Cancer. 2016 Jan 1;122(1):84-90
pubmed: 26439132
BMC Cancer. 2021 Apr 7;21(1):363
pubmed: 33827469
N Engl J Med. 2018 Dec 27;379(26):2495-2505
pubmed: 30345884
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Hum Mutat. 2019 Sep;40(9):1557-1578
pubmed: 31131967
Cancer Discov. 2015 Nov;5(11):1137-54
pubmed: 26463832
Oncologist. 2016 Jul;21(7):832-9
pubmed: 27286788
Breast Cancer. 2021 Nov;28(6):1167-1180
pubmed: 32862296
J Hum Genet. 2018 Feb;63(2):213-230
pubmed: 29192238
PLoS One. 2021 Jan 11;16(1):e0236907
pubmed: 33428613
NPJ Breast Cancer. 2021 Aug 19;7(1):107
pubmed: 34413315
Cancer Epidemiol Biomarkers Prev. 2012 Jan;21(1):134-47
pubmed: 22144499
Healthcare (Basel). 2022 Oct 25;10(11):
pubmed: 36360466
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
N Engl J Med. 2019 Dec 19;381(25):2391-2402
pubmed: 31562799
Cancer Res. 2006 Aug 15;66(16):8297-308
pubmed: 16912212